Recent advances in secondary stroke prevention include new evidence in hypertension, nutrition, anticoagulation, antiplatelet therapy, intracranial stenosis, percutaneous closure of patent foramen ovale, and lipid-lowering therapy. Individualized therapy for hypertension based on phenotyping with plasma renin and aldosterone markedly improves blood pressure control in patients with resistant hypertension. A Mediterranean diet can reduce the risk of stroke by nearly half. The diagnosis and treatment of metabolic vitamin B12 deficiency, and B vitamins to lower homocysteine, can reduce the risk of stroke by approximately 30%. There are problems with clopidogrel that can be overcome by using ticagrelor, and new anticoagulant drugs markedly improve anticoagulation for stroke prevention, particularly in atrial fibrillation. There are pharmacokinetic problems with dabigatran that deserve attention. Intensive medical therapy is better than stenting for intracranial stenosis, and new therapies directed at proprotein convertase subtilisin-kexin type 9 (PCSK9) will revolutionize lipid-lowering therapy. In the past, it was estimated that rational therapy could reduce recurrent stroke by about 80%. With recent advances, we should be able to do even better.
Keyphrases
- atrial fibrillation
- antiplatelet therapy
- percutaneous coronary intervention
- blood pressure
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- acute coronary syndrome
- direct oral anticoagulants
- heart failure
- healthcare
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- mental health
- physical activity
- hypertensive patients
- fatty acid
- heart rate
- venous thromboembolism
- high throughput
- coronary artery disease
- mesenchymal stem cells
- metabolic syndrome
- blood glucose
- adipose tissue
- skeletal muscle
- arterial hypertension
- cerebral ischemia
- replacement therapy
- angiotensin converting enzyme